Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Ivanenko

Sleep Medicine Elk Grove Village, IL Medical Doctor

NPI 1255308334 CMS profile 193306

800 Biesterfield Rd, Suite 510, Elk Grove Village, IL 60007

Open in the dashboard

General payments

$14,044

96 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Ivanenko of Elk Grove Village, IL is reported in the CMS Open Payments database as having received $14,044 across 96 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Sleep Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $260 4
2024 General $822 9
2023 General $10,743 22
2022 General $598 10
2021 General $679 14
2020 General $252 8
2019 General $690 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Ivanenko
  • Sleep Medicine median
  • Middle half of Sleep Medicine
  • National median

In program year 2025, general payments to Anna Ivanenko were reported at $260. Among 263 Sleep Medicine profiles paid that year, the median was $337 and the middle half received between $114 and $1,241.

Show as a table
Year Anna Ivanenko Sleep Medicine median Middle half National median
2019 $690 $206 $79–$855 $163
2020 $252 $170 $48–$1,437 $114
2021 $679 $178 $53–$1,297 $132
2022 $598 $313 $95–$1,332 $149
2023 $10,743 $307 $117–$1,081 $160
2024 $822 $308 $100–$1,432 $164
2025 $260 $337 $114–$1,241 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $10,235 18 payments
  2. Tris Pharma Inc $861 17 payments
  3. Neos Therapeutics, LP $781 8 payments
  4. Ironshore Pharmaceuticals Inc. $640 7 payments
  5. ITI, Inc. $354 3 payments
  6. Corium, Inc. $237 3 payments
  7. Supernus Pharmaceuticals, Inc. $224 2 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $112 6 payments
  9. Axsome Therapeutics, Inc. $94 1 payment
  10. Harmony Biosciences LLC $89 4 payments
  11. Other $419 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $8,712 3 payments
  2. Food and Beverage $4,412 90 payments
  3. Travel and Lodging $921 3 payments
Products named General payments · program years 2019–2025
  1. XYWAV $10,132 13 payments
  2. Adzenys XR-ODT $765 7 payments
  3. Dyanavel XR Adhd $404 6 payments
  4. Dyanavel XR Adhd $323 4 payments
  5. JORNAY PM $318 3 payments
  6. Quillivant $254 4 payments
  7. Azstarys $237 3 payments
  8. CAPLYTA $230 2 payments
  9. QELBREE $224 2 payments
  10. Quillichew ER $212 2 payments
  11. Other $1,855 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

100

Median for Psychiatry: 574

Drug cost

$689

Median for Psychiatry: $27,624

Branded share of claims

15%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Temazepam Generic 13 $164
Amitriptyline Hcl Generic 12 $146
Sertraline Hcl Generic 17 $124
Clonazepam Generic 13 $90
Duloxetine Hcl Generic 19 $76
Bupropion Hcl Sr Bupropion Hcl Brand 15 $56
Zolpidem Tartrate Generic 11 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $230
$230 — —
XYWAV
  • JAZZ PHARMACEUTICALS INC. $140
$140 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $117
$117 — —
Adzenys XR-ODT
  • Neos Therapeutics, LP $101
$101 — —
Sunosi
  • Axsome Therapeutics, Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

96 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sleep Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record